Galapagos NV
GLPG•NASDAQ•Healthcare•Biotechnology

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOHenry Gosebruch
Founded1999
IPO DateMay 6, 2005
Employees704
CountryBelgium
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyEUR - EUR
TypeStock

Contact Information

Websitewww.glpg.com
Phone32 1 534 29 00
Address
Generaal De Wittelaan L11 A3 Mechelen, 2800 Belgium

Corporate Identifiers

CIK0001421876
CUSIP36315X101
ISINUS36315X1019
SIC2834

Leadership Team & Key Executives

Henry Gosebruch
Chief Executive Officer and Executive Director
Aaron L. Cox
Chief Financial Officer
Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D.
Head of Investor Relations
Fred W. Blakeslee II
Executive Vice President and General Counsel
Marieke Vermeersch
Head of Corporate Communication
Annelies Missotten
Executive Vice President and Chief Human Resources Officer
Ellen Van Der Aar
Head of Development
Alice Dietrich
Head of Medical Affairs
Patrik Ringblom
Head of Strategy and US Lead
Dr. Jeevan Shetty
Head of Clinical Development Oncology